New hope for Hard-to-Treat lung cancer: drug combo targets bulky tumors

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 75 years; * ECOG performance status score of 0 or 1; * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); * Unresectable stage III NSCLC (per AJCC 9th edition staging), with primary tumor diameter T ≥ 5 cm or regional metastatic lymph node short-axis diameter N ≥ 2 cm; * Expected survival time of at least 3 months; * No prior anti-tumor treatment before enrollment, including radiotherapy, chemotherapy, surgery and targeted therapy; * Adequate function of major organs; * Female subjects must have a negative pregnancy test result and be willing to use effective contraception; * Subjects voluntarily participate in the study, sign the informed consent form, with good compliance and willingness to complete follow-up. Exclusion Criteria: * Subjects with known positive EGFR mutation or positive ALK fusion. * Histologically or cytologically confirmed mixed SCLC and NSCLC, large cell neuroendocrine carcinoma, and sarcomatoid carcinoma. * Participation in another clinical trial within 4 weeks prior to the first study dose or within 5 half-lives of the study drug, whichever is shorter. * Subjects who have received systemic immunosuppressive therapy within 2 weeks before the first dose, or those who are expected to require systemic immunosuppressive drugs during the study treatment period. * Subjects with congenital or acquired immunodeficiency, such as HIV infection; or with a history of autoimmune diseases. * Active hepatitis B, hepatitis C, or co-infection with both hepatitis B and hepatitis C. * Uncontrolled third-space effusions, such as massive pleural effusion, ascites or pericardial effusion. * History of other malignant tumors (other than NSCLC) within 5 years prior to screening. * Subjects with prior interstitial lung disease requiring hormone therapy. * Subjects with severe cardiovascular and cerebrovascular diseases. * History of severe bleeding events or arterial/venous thromboembolic events. * Severe infection within 4 weeks before the first dose; evidence of active tuberculosis infection within 1 year prior to the first dose; active fungal, bacterial and/or viral infections requiring systemic treatment. * Subjects with prior or planned allogeneic bone marrow transplantation or solid organ transplantation. * History of live attenuated vaccination within 28 days before the first dose, or planned live attenuated vaccination during the study period; pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptive measures. * Known hypersensitivity, anaphylactic reaction or intolerance to adebrelimab, chemotherapy agents, or their excipients. * Subjects with a known history of psychoactive substance abuse, alcoholism or drug addiction.